About Transcription cofactor vestigial-like protein 2
Transcription cofactor vestigial-like protein 2 (VGLL2) is a protein
from Homo sapiens identified by UniProt accession
Q8N8G2, 317 residues long.
MolForge cross-references it against 0 known binders and
47 disease associations.
Target properties
| Protein name | Transcription cofactor vestigial-like protein 2 |
|---|
| UniProt accession | Q8N8G2 |
|---|
| Gene | VGLL2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 317 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (47)
Diseases linked to this target (Open Targets).
- electrocardiography · score 0.49
- neurodegenerative disease · score 0.42
- body height · score 0.34
- aspartate aminotransferase measurement · score 0.29
- chronic obstructive pulmonary disease · score 0.28
- cardiac arrhythmia · score 0.28
- BMI-adjusted waist circumference · score 0.28
- creatine kinase measurement · score 0.27
- systolic blood pressure · score 0.27
- diastolic blood pressure · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8N8G2-F1 | alphafold | PREDICTED | 54.22 | — |
Amino-acid sequence (317 residues)
MSCLDVMYQV YGPPQPYFAA AYTPYHQKLA YYSKMQEAQE CNASPSSSGS GSSSFSSQTP ASIKEEEGSP EKERPPEAEY INSRCVLFTY FQGDISSVVD EHFSRALSQP SSYSPSCTSS KAPRSSGPWR DCSFPMSQRS FPASFWNSAY QAPVPPPLGS PLATAHSELP FAAADPYSPA ALHGHLHQGA TEPWHHAHPH HAHPHHPYAL GGALGAQAAP YPRPAAVHEV YAPHFDPRYG PLLMPAASGR PARLATAPAP APGSPPCELS GKGEPAGAAW AGPGGPFASP SGDVAQGLGL SVDSARRYSL CGASLLS
Explore Transcription cofactor vestigial-like protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets